SHIONOGI ENTERS INTO LICENSE AGREEMENT WITH PHARMBIO KOREA FOR OSPEMIFENE OSAKA, Japan, April 17, 2018 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi"), today announced that Shionogi Inc., its U.S. subsidiary, has entered into a license agreement with Pharmbio Korea Inc.(Head Office: Seoul, South Korea; Chairman:BongGil Nam; hereafter "Pharmbio") for the development and commercialization in South Korea of ospemifene (generic name),the only oral prescription medication for the treatment of symptomatic vulvar and vaginal...
|
